|
Characteristics of three hemoglobin-based oxygen carriers being tested in advanced clinical trials |
|||
| Product name |
|||
|
|
|||
| Details |
PolyHeme® |
Hemopure® (HBOC-201) |
HemoLink™ (Hb-raffimer) |
|
|
|||
| Company |
Northfield Laboratories (Evanston, IL, USA) |
Biopure Corporation (Cambridge, MA, USA) |
Hemosol Inc. (Toronto, Canada) |
| Modification method |
Pyridoxylation and glutaraldehyde polymerization (polymer) |
Glutaraldehyde polymerization (polymer) |
Crosslinking with o-raffinose (oligomer) |
| Hemoglobin source |
Human hemoglobin |
Bovine hemoglobin |
Human hemoglobin |
| Hemoglobin concentration (g/dl) |
10 |
13 |
10 |
| Molecular weight |
Not reported (< 64 kDa; 1.0%) |
Average molecular weight: 250 kDa |
<64 kDa: <5% |
| 64–500 kDa: >90% |
|||
| >500 kDa: <3% |
|||
| pH |
Not reported |
7.6–7.9 |
7.5 |
| P50 (torr) |
26–32 |
38 |
52 |
| Viscosity (cP) |
Not reported |
1.3 |
1.14 |
| Shelf life |
>1 year |
>1 year |
>1 year |
|
HBOC, hemoglobin-based oxygen carrier; P50, partial pressure of oxygen at which hemoglobin is 50% saturated. | |||
Greenburg and Kim Critical Care 2004 8(Suppl 2):S61 doi:10.1186/cc2455 |
|||